secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001493152-24-016069
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix
--------------------------------------------------------------------------------

- CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).
- Planning Phase 1/2 clinical trial in Australia for diabetic foot ulcers in 2025, results expected Q3 2025.
- FDA IND clearance for CybroCell Phase 1/2 trial for degenerative disc disease, conditional on master cell bank.
- Expect to complete remaining CYWC628 pre-clinical studies (toxicity, dose titration) in Q3 2024.
- Manufacturing: planning CDMO transfer; master cell bank, working cell bank, and drug product by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/0001493152-24-016069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-016069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer